Global Electro-Medical Devices in Alzheimer’s Treatment Market – Industry Trends and Forecast to 2029

Global Electro-Medical Devices in Alzheimer’s Treatment Market, By Drug Class (Cholinergic, Memantine, Combined Drug, AChE inhibitors, Immunoglobulins), Drug Type (Cholinesterase Inhibitors, NMDA Receptor Antagonists), Therapeutics (Cholinesterase Inhibitors, NMDA Receptor Antagonists, Other Therapeutics) – Industry Trends and Forecast to 2029

Market Analysis and Size

Alzheimer's disease (A.D.) is a neurodegenerative ailment that worsens over time and targets the brain's nerve cells or neurons. It causes memory loss, loss of cognitive and verbal abilities, and behavioural changes. The number of people suffering from Alzheimer's disease is rapidly increasing, but only around one in four of these individuals receive a diagnosis.

Data Bridge Market Research analyses that the electro-medical devices in Alzheimer's treatment market which was USD 3.76 billion in 2021, would rocket up to USD 8.03 billion by 2029, and is expected to undergo a CAGR of 9.95% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Market Definition

Alzheimer's disease is the most dominant, age-related neurodegenerative ailment that causes memory loss, drastic changes in personality and behaviour, and eventually the inability to perform basic daily tasks. The pathogenesis of the disease is associated with the build up a toxic beta-amyloid peptide in brain tissues, which causes substantial cellular stress in brain cells and is linked to neuro-inflammation, mitochondrial malfunction, and finally the slow death of neuronal cells.

Electro-Medical Devices in Alzheimer’s Treatment Market Dynamics

Drivers

• Research and development activities

The market for treating Alzheimer's disease (A.D.) is seeing an increase in R&D investments and collaborations as a result of new treatment technologies. The Alzheimer's association works to increase government funding for Alzheimer's research and offers financial support to researchers looking for novel therapy strategies. The A.D. market is seeing the emergence of technologies including amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors and anti-amyloid inhibitors.

• Rising incidence of the disease

The market for Alzheimer's treatments is expanding as a result of the rising incidence of the disease. The most common type of dementia is Alzheimer's. The USA Alzheimer's Association predicts that by 2025, the number of Americans living with Alzheimer's disease would increase by at least 14% across all U.S. states due to an ageing population. Globally, it is predicted that the number of new cases of Alzheimer's will increase by 35 percent to 615,000 by 2030 and by 110 percent to 959,000 by 2050. As a result, it is anticipated that the global market for treating Alzheimer's disease would rise due to the disease's rising prevalence.

Opportunities

Additionally, because Alzheimer's is an age-related disease and the elderly population is more susceptible to neurological disorders like them, the region's ageing population growth is predicted to increase the burden of Alzheimer's disease. For instance, the U.S. geriatric population (those 65 and older) was 53,340,00 in 2019, compared to 6,602,000 in Canada and 9,462,000 in Mexico, according to the United Nations' World Population Ageing Highlight report from the same year. By 2050, however, those numbers are expected to rise to 26,416,000 in Mexico, 11,436,000 in Canada, and 84,813,000 in the US.

Restraints/Challenges

• Diagnosis of A.D. is difficult

The development of the global market for Alzheimer's disease treatments is anticipated to be constrained by a lack of methods for diagnosing Alzheimer's Disease (A.D.). The diagnosis of A.D. is difficult since there is no conclusive blood test, brain scan, or physical exam, and so many illnesses can cause symptoms like dementia, which is the main clinical symptom of A.D.

• Lack of accurate and timely A.D.

Specialists such as neurologists, neuropsychologists, geriatricians, and geriatric psychiatrists employ a range of procedures for diagnosis to confirm dementia due to the lack of a single diagnostic test, but it is still challenging to discover the reason, leading to late diagnosis. Lack of accurate and timely A.D. diagnosis hinders market expansion since it results in fewer diagnosed cases and, as a result, lower A.D. use.

This electro-medical devices in Alzheimer’s treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the electro-medical devices in Alzheimer's treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Electro-Medical Devices in Alzheimer’s Treatment Market

The COVID-19 pandemic's emergence had an effect on the market for diagnostic and therapeutic products for Alzheimer's disease. Diagnostic and therapeutic procedures suffered globally as a result of fewer people visiting hospitals and diagnostic facilities due to lockdown restrictions imposed by different governments around the world. Additionally, a number of research noted COVID-19's detrimental effects on Alzheimer's patients, which is also anticipated to have an effect on the market under investigation. For instance, it was found that individuals with dementia have the highest risk of dying from COVID-19 in the article "Alzheimer's and Parkinson's illnesses predict distinct COVID-19 outcomes, a U.K. Biobank study," released in November 2020.

Recent Development

• In January 2020, For an upfront payment of $75 million and up to $635 million in potential further development and commercialization milestone payments, US-based Biogen Inc. bought Pfizer Inc.
• In October 2021, to determine the safety of the novel Alzheimer's medication CMS121 in people, Salk Institute started a phase 1 clinical research.

Global Electro-Medical Devices in Alzheimer’s Treatment Market Scope

The electro-medical devices in alzheimer’s treatment market is segmented on the basis of drug class, drug type, therapeutics. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

• Cholinergic
• Memantine
• Combined Drug
• AChE inhibitors
• Immunoglobulins

Drug Type

• Cholinesterase Inhibitors
• NMDA Receptor Antagonists

 Therapeutics

• Cholinesterase Inhibitors
• NMDA Receptor Antagonists
• Other Therapeutics

Electro-Medical Devices in Alzheimer’s Treatment Market Regional Analysis/Insights

The electro-medical devices in Alzheimer’s treatment market is analysed and market size insights and trends are provided by country, drug class, drug type, therapeutics as referenced above.

The countries covered in the electro-medical devices in Alzheimer’s treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is the largest Alzheimer’s disease treatment market region in 2022.

Asia-Pacific is expected to be the fastest growing region in the forecast period of 2022-2029.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Electro-Medical Devices in Alzheimer’s Treatment Market Share Analysis

The electro-medical devices in Alzheimer’s treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to electro-medical devices in Alzheimer’s treatment market.

Some of the major players operating in the electro-medical devices in Alzheimer’s treatment market are:

• Allergan (Ireland)
• Eisai Co. Ltd., (Japan)
• Novartis AG, (Switzerland0
• Pfizer Inc., (U.S.)
• Merz Pharma, (Germany)
• H. Lundbeck A/S (Denmark)
• AstraZeneca (U.K.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Johnson & Johnson Private Limited (U.S.)
• A.C. Immune S.A. (Switzerland)
• Forest Laboratories, Inc. (U.S.)
• TauRx Pharmaceuticals Ltd (U.K.)
• VTV Therapeutics (U.S.)
• Eli Lilly and Company (U.S.)